PERSPECTIVE
The NKF-KDOQI (National Kidney FoundationKidney Disease Outcomes Quality Initiative) definition and staging system for chronic kidney disease (CKD), 1 which published in 2002, facilitated the development of clinical practice guidelines for managing the complications associated with kidney disease for stages earlier than kidney failure. Subsequent guidelines from NKF-KDOQI include 2 publications concerning bone metabolism and disease in patients with CKD (recommendations for adults 2 In 2009, KDIGO (Kidney Disease: Improving Global Outcomes) published clinical practice guidelines on the diagnosis, evaluation, prevention, and treatment of CKD-mineral and bone disorders 4 and the care of kidney transplant recipients. 5 These guidelines also provided opinion-based recommendations regarding measurement of 25(OH)D in patients with CKD stages 3-5, including those receiving dialysis, and in CKD stages 1-5 in kidney transplant recipients. The recommendations by KDIGO regarding 25(OH)D testing and supplementation did not necessarily mirror the KDOQI recommendations.
During the past decade, knowledge of the biological mechanisms of vitamin D for bone maintenance in individuals with all stages of CKD has greatly expanded. However, no consensus currently exists within the medical community regarding methods for 25(OH)D supplementation or optimal 25(OH)D levels in individuals with CKD.
2-4, [6] [7] [8] This lack of consensus was highlighted in a report from the Institute of Medicine (IOM) Committee to Review Dietary References Intakes for Vitamin D and Calcium published in 2011. 9 In this article, we focus on the debate regarding thresholds for 25(OH)D supplementation and risks and benefits of 25(OH)D supplementation for adults with stages 3-5 non-dialysis-dependent CKD.
BACKGROUND

Chemistry and Biological Activity
Vitamin D, an essential nutrient for all individuals regardless of CKD status, may be categorized into 2 major forms: vitamin D 2 and vitamin D 3 . Vitamin D 2 (ergocalciferol) is produced by UV irradiation of yeast ergosterol and frequently is added to processed foods such as cereals and bread. 10 Vitamin D 3 (cholecalciferol) is synthesized in the skin by UVB radiation of 7-dehydrocholesterol 10 and occurs naturally in certain foods such as oily fish. Also, in the United States, synthetic vitamin D 3 is added to milk. Although both vitamin D 2 and D 3 may be synthesized commercially, their biological activity is limited until they undergo hydroxylation by 25- 9 Instead, the production of 1a-hydroxylase in the kidney is regulated tightly by plasma parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), and serum calcium and phosphorus levels.
10
The dominant role of active vitamin D is to interact with PTH to maintain serum calcium and phosphorus levels within a narrow range for bone maintenance. 15 We now know that the vitamin D-PTH axis also includes FGF-23, which is produced predominantly by osteoblasts and osteocytes and regulates renal tubular phosphate reabsorption by inhibition of the solute carrier 34 member family 1 and 3 sodium-dependent cotransporters in the proximal tubules. 15 17 which leads to cellular resistance to FGF-23. 15 Thus, as glomerular filtration rate (GFR) decreases to , 60 mL/min/1.73 m 2 (CKD stage 3a), the ability to excrete a phosphorus load and maintain calcium homeostasis becomes progressively impaired (Fig 2) . In patients with non-dialysis-dependent CKD stages 3-5 in whom plasma PTH levels are progressively increasing and remain persistently above the assay's upper limit of normal despite correction of modifiable factors (hyperphosphatemia, hypocalcemia, and vitamin D deficiency), the KDIGO guideline suggested initiating treatment with active vitamin D such as calcitriol or vitamin D analogues. The KDIGO guideline acknowledged a lack of established consensus regarding optimal PTH levels for CKD. However, KDIGO recommended that patients with PTH levels above the upper limit of normal for the PTH assay be screened for 25 . 4 The level of evidence supporting these recommendations was graded as 2C by KDIGO, indicating that recommendations were based on low-quality evidence, meaning the true effect of the intervention could be substantially different from the estimated effect (Table 1) . Table 1 .
Existing evidence at the time the KDOQI and KDIGO guidelines were published suggested that 25(OH)D supplementation may be a more cost-effective and safer alternative for management of secondary hyperparathyroidism in non-dialysis-dependent CKD. 30 However, findings from studies examining the association between ergocalciferol or cholecalciferol use and reduction in PTH levels among patients with stages 2-4 CKD or non-dialysis-dependent stage 5 CKD have been inconsistent. [31] [32] [33] [34] [35] [36] [37] [38] A summary of these studies by Kandula et al 39 found that many, but not all, patients in these studies achieved 25(OH)D levels . 30 ng/mL with ergocalciferol or cholecalciferol supplementation. In addition, not all studies showed significant declines in PTH levels with 25(OH)D supplementation compared with baseline values. 34, 38, 40 Differences in doses of 25(OH)D supplementation, 41 adiposity, 42 length of treatment, 39 and CKD severity may have all contributed to the lack of congruent findings across studies.
RECENT CLINICAL FINDINGS
In 2010, the first randomized clinical trial of 25(OH)D versus active vitamin D for the management of secondary hyperparathyroidism in patients with stages 3-4 CKD was published. 30 In this randomized, blinded, 3-month trial, adults with 25(OH)D levels # 20 ng/mL and either stage 3 CKD and PTH levels . 100 pg/mL or stage 4 CKD and PTH levels . 150 pg/mL were randomly assigned to either cholecalciferol, 4,000 IU, daily for 1 month followed by 2,000 IU daily for 2 months or doxercalciferol 1 mg tablets daily for 3 months. Allocation was stratified by CKD stage. Exclusion criteria for this study included PTH level . 400 pg/mL, corrected calcium level . 9.7 mg/dL, serum phosphorus level . 5.0 mg/dL, and use of calcimimetics or vitamin D therapy 30 days before enrollment. A total of 55 patients were randomly assigned and 47 of them had at least one follow-up visit (22 and 25 in the cholecalciferol and doxercalciferol groups, respectively).
In analyses by CKD stage, relative change in PTH levels for CKD stage 3 was 215.9% 6 20.3% in cholecalciferol-treated individuals and 225.1% 6 37% for the 13 doxercalciferol-treated patients. For CKD stage 4, relative change in PTH levels was 21.3% 6 33% in the 7 cholecalciferol-treated individuals, but 230.3% 6 29.3% for the 8 doxercalciferol-treated individuals. Overall, PTH levels decreased by 10% 6 31% in the cholecalciferol group and 27% 6 34% in the doxercalciferol group. In the group that received cholecalciferol, 25(OH)D levels increased from a baseline mean of 14.0 6 6.1 to 37.l 6 10.1 ng/mL at study completion. Overall, there was no significant difference in PTH lowering between the cholecalciferol and doxercalciferol groups, but sample sizes were small. No change in 25(OH)D levels was noted in the group that received doxercalciferol. 30 The findings that cholecalciferol had a greater impact on lowering PTH levels in patients with CKD stage 3 versus stage 4 is consistent with several other published studies that demonstrated differences in PTH lowering with either cholecalciferol or ergocalciferol by CKD stage. 35, 36, 38 Other studies have shown no significant changes in PTH levels with cholecalciferol, 2,000 IU, daily in children with nondialysis-dependent stages 2-5 CKD 43 or with ergocalciferol in adults (CKD stages 3-4) after 6 months of therapy. Differences in PTH lowering with 25(OH)D supplementation by CKD severity may be a function of the inhibition of 1a-hydroxylase activity by FGF-23, PTH fragments, and uremic solutes, factors that are higher in CKD stages 4-5 versus stage 3. 39 In patients receiving dialysis, studies have not consistently demonstrated significant lowering of PTH levels with 25(OH)D supplementation. Despite the large amount of research on vitamin D and its association with health that has been produced over the past decade, no consensus has emerged within the medical community regarding 25(OH)D thresholds that define 25(OH)D deficiency or insufficiency. 10 In the last decade, many studies have focused on 25(OH)D levels , 30 ng/mL for disease outcomes. 46 This threshold is supported by a clinical guideline on evaluation, treatment, and prevention of vitamin D deficiency from the Endocrine Society, which defines 25(OH)D levels , 20 ng/mL as a state of deficiency and 20-29 ng/mL as a state of insufficiency. 8 In contrast, the Pediatric Endocrine Society recommends that a 25(OH)D level . 20 ng/mL be used to define 25(OH)D sufficiency, with 25(OH)D levels of 15-20 and # 15 ng/mL defining insufficiency and deficiency, respectively. 47 The American Academy of Pediatrics also suggests that 25(OH)D levels $ 20 ng/mL define sufficient 25(OH)D. 48 The selection of 25(OH)D levels $ 30 ng/mL as a marker of 25(OH)D sufficiency was based on several published studies reporting maximal PTH suppressed at this 25(OH)D threshold. 27, 49, 50 Studies showing maximal PTH suppression at a 25(OH)D threshold of 30 ng/mL included one based on a female population with osteoporosis, many of whom were receiving bisphosphonates (which increases PTH levels), and one that used a statistical approach that did not account for the nonlinear association between PTH and 25(OH)D levels. 51 None included adults with CKD. Sai et al 52 summarized data from 70 studies that examined serum 25(OH)D levels by serum PTH levels in a variety of populations and settings. In 59 studies, no consistent 25(OH)D cutoff was associated with maximal PTH suppression. PTH values demonstrated a plateau at serum 25(OH)D levels ranging as low as 15 ng/mL to as high as 50 ng/mL, whereas 8 studies showed no plateau, but rather a linear and indirect association between serum PTH and 25(OH)D levels. The other 3 studies showed no association between 25(OH)D and serum PTH levels. 52 It should be noted that none of these studies focused on populations with CKD.
Due to the controversy regarding 25(OH)D thresholds for treatment, the association between 25(OH)D levels and clinical outcomes and the rapid growth in vitamin D testing and supplementation in North America, the US and Canadian governments requested that the IOM review the existing evidence regarding 25(OH)D requirements and identify dietary reference intakes. The IOM Committee to Review Dietary References Intakes for Vitamin D and Calcium examined the evidence, including consideration of the impact of 25(OH)D intake on chronic disease indicators such as cancer, cardiovascular disease, diabetes, and CKD and other nonchronic disease indicators and assessed the ability of each outcome/indicator to serve as the basis for specifying adequate or excess intake. 9 The committee did not create a definition for 25(OH)D deficiency or sufficiency per se, but instead defined 25(OH)D level , 12 ng/mL as a state of risk of deficiency 9 and stated that some, but not all, individuals may be at risk for insufficiency with 25(OH)D levels of 12-20 ng/mL. 9 The report highlighted the fact that enhancing calcium absorption remains the key role of vitamin D; thus, the effects of 25(OH)D deficiency may depend on calcium intake. Their review of the existing evidence revealed a trend toward maximum calcium absorption at 25(OH)D levels of 12-20 ng/mL, with no further increase at higher 25(OH)D levels. The terms risk of deficiency and risk of insufficiency were used to emphasize the likely heterogeneity of effects of low 25(OH)D levels on bone maintenance across degrees of calcium intake. 9 Individuals with low 25(OH)D levels may not be at risk for rickets or osteomalacia if calcium intake is adequate, but no amount of vitamin D can compensate for inadequate calcium intake. 9 The recommended dietary allowance was set as 600 IU daily for children and adults (male and female) aged 1-69 years. Determining a one-size-fits-all threshold for 25(OH)D supplementation is especially problematic for patients with CKD if these thresholds are based on maximal suppression of PTH. First, there is no consensus regarding optimal PTH levels for CKD stages and the distribution of serum PTH levels across the spectrum of 25(OH)D levels likely differs by CKD severity 30 due to differences in 1a-hydroxylase activity. This issue is complicated further in minority racial/ethnic groups, which carry a disproportionate burden of CKD. [55] [56] [57] [58] Darker skin pigmentation is associated with a leftward shift in the distribution of 25(OH)D levels 59 and studies have reported that only a small fraction of African Americans have sufficient 25(OH)D levels. [60] [61] [62] Persons with African ancestry demonstrate PTH plateaus at much lower 25(OH)D levels than whites. 63, 64 The association between 25(OH)D levels and bone mineral density and response to 25(OH)D supplementation with regard to bone mineral density also differs by race/ethnicity. 63, [65] [66] [67] [68] 74 Further research is needed to clarify the role of GC variants on 25(OH)D levels and clinical outcomes, especially in patients with CKD.
Non-Bone Disease Indications for 25(OH)D Supplementation
Over the past 2 decades, emerging research has demonstrated that vitamin D receptors exist in most tissues and cells of the human body.
10 Such findings have fueled investigations on the role of 25(OH)D in multiple chronic diseases, 75, 76 including diabetes, heart disease, cancer, autoimmune diseases, and hypertension, [77] [78] [79] [80] and has led to marked increases in serologic testing and use of vitamin D supplements. 81, 82 A range of population and clinical research has implicated less severe vitamin D deficiency as a potential risk factor for several chronic diseases, including hypertension, obesity, diabetes, cardiovascular diseases, autoimmune diseases, asthma, and depression. 13, 77, 78, 80, [83] [84] [85] [86] [87] [88] [89] [90] The 1a-hydroxylase enzyme is located primarily in the kidney, and nephrectomy or reduced kidney function equate with marked reduction in conversion of 25(OH)D to 1,25(OH) 2 D. 91, 92 However, the discovery of 1a-hydroxylase in the placenta, gastrointestinal tract, skin, blood vessels, and granulomatous tissue demonstrated that 1,25(OH) 2 D production is not limited to the kidney. [91] [92] [93] Vitamin D receptors also have been located in multiple tissues not associated with calcium or phosphorus homeostasis, and vitamin D-responsive elements have been discovered in numerous human genes. Such discoveries promoted the autocrine/paracrine hypothesis that local production of active vitamin D may promote health by enhancing cellular immunity or endothelial function. 93 However, the contribution of extrarenal 1a-hydroxylase to vitamin D metabolism remains largely unknown. 93 Low 25(OH)D levels also have been associated with rapid decline of kidney function and higher mortality in adults with established CKD. 94 All-cause mortality is increased significantly at the low end of the 25(OH)D distribution in US adults with and without CKD. 95, 96 However, 25(OH)D levels may be influenced by multiple factors, such as sun exposure and diet, which may correlate with other health behaviors. Observational studies remain an efficient method for examining associations between chronic diseases and 25(OH)D levels, but they cannot determine whether these associations are causal.
After reviewing the evidence linking 25(OH)D levels and supplementation with chronic diseases published through 2010, the IOM vitamin D committee concluded that no level I evidence from randomized controlled trials demonstrated a clinical impact of 25(OH)D on a chronic disease other than modulating bone disease and turnover. 9 NKF-KDOQI and KDIGO guidelines did not recommend supplementing 25(OH)D for non-bone-related chronic diseases in patients with CKD.
2-4 Similarly, the Endocrine Society clinical practice guideline did not recommend prescribing 25(OH)D supplements beyond recommended daily needs for the primary or secondary prevention of cardiovascular disease or mortality or to improve quality of life. 8 However, this guideline recommended 25(OH)D supplementation for fall prevention (a noncalcemic benefit of vitamin D) and for prevention of rickets and osteomalacia (a calcemic benefit). 8 The IOM subsequently published a commentary that outlined their disagreement with the Endocrine Society's recommendation of 25(OH)D supplementation for fall risk. 51 The IOM specifically pointed out major flaws in a meta-analysis of studies examining the association between 25(OH)D supplementation and fall risk published in 2009. 97 The IOM committee reanalyzed data from this metaanalysis and found no significant dose-response relationship between fall risk and achieved 25(OH)D level. 51 Currently, use of 25(OH)D to maintain skeletal health remains the only health indicator with enough evidence to create dietary reference intakes. 9 
RESEARCH RECOMMENDATIONS AND CONCLUSION
Given the widespread testing and use of 25(OH)D supplements, there remains an urgent need for wellexecuted clinical trials investigating the risks and benefits of 25(OH)D supplementation in adults and children with CKD.
98 Studies need to determine 25(OH)D thresholds for supplementation and longterm goals for treatment and subsequent risks and benefits. Such studies will need to address the fact that multiple facets of 25(OH)D treatment, such as thresholds to initiate treatment, dose, and maintenance, may differ across race/ethnicity and by CKD stages. (Fig 3) .
To date, a few clinical trials have suggested that 25(OH)D supplementation lowers PTH levels in individuals with CKD stage 3, but may be less effective in individuals with stages 4-5 CKD. Given the limited amount of level 1 evidence regarding the risks and benefits of 25(OH)D supplementation, clinicians must continue to use their best clinical judgment and individualize treatment decisions. 4 Clinicians also must be cognizant of the current lack of standardization of 25(OH)D measurement, so caution must be used when comparing and interpreting studies of 25(OH)D thresholds for clinical outcomes. To date, no clinical practice guideline has recommended 25(OH)D supplementation for any non-bone-related chronic medical condition, except for falls, due to lack of strong evidence. Ongoing clinical trials such as the DIVINE (Dialysis Infection and Vitamin D in New England) Study (ClinicalTrials.gov identifier NCT00892099) and VITAL (Vitamin D and Omega-3 Trial; ClinicalTrials.gov identifier NCT01169259) hopefully someday will answer the many clinical questions regarding the role of 25(OH)D in health and disease and provide better guidance for 25(OH)D testing and supplementation. Dr Choi is Vice Chair, Education. Dr Martin was a member of the KDOQI Work Group responsible for the clinical practice guideline for bone metabolism in adults with CKD.
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